| Literature DB >> 30141348 |
Vincenzo Di Nunno1, Alessia Cimadamore2, Matteo Santoni3, Marina Scarpelli2, Michelangelo Fiorentino4, Chiara Ciccarese5, Roberto Iacovelli5, Liang Cheng6, Antonio Lopez-Beltran7, Francesco Massari1, Rodolfo Montironi2.
Abstract
Entities:
Keywords: MET inhibitor; bone metastasis; cabozantinib; castration-resistant prostate cancer; metastatic RCC; multityrosine kinases inhibitor; osteoblastic activation; renal cell carcinoma; target therapy; angiogenesis
Mesh:
Substances:
Year: 2018 PMID: 30141348 DOI: 10.2217/fon-2018-0158
Source DB: PubMed Journal: Future Oncol ISSN: 1479-6694 Impact factor: 3.404